दवा संदर्भ
Zenocutuzumab
Zenocutuzumab is a medicine in the class oncology. It is used for non-small cell lung cancer.
- दवा वर्ग: Oncology
- उपयोग: non-small cell lung cancer
अंतिम अपडेट स्रोत: US FDA label
केवल स्वास्थ्य पेशेवरों के लिए — मात्र संदर्भ हेतु। यह पृष्ठ संक्षिप्त सारांश है, चिकित्सकीय सलाह नहीं है और आधिकारिक लेबल या नैदानिक निर्णय का विकल्प नहीं है। दवा लिखने या देने से पहले हमेशा जाँच करें।
इस पृष्ठ की नैदानिक सामग्री केवल अंग्रेज़ी में उपलब्ध है।
मुख्य तथ्य
- दवा वर्ग
- Oncology
- सामान्य रूप
- इंजेक्शन
- सामान्य मात्राएँ
- 20 mg/ml
- ब्रांड नाम
- 1
- देश और बाज़ार
- 1
उपयोग
यह कैसे काम करती है
Bispecific antibody that binds the extracellular domains of HER2 and HER3, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3. It decreases cell proliferation and PI3K-AKT-mTOR signaling, and mediates antibody-dependent cellular cytotoxicity.
वयस्कों की सामान्य खुराक (लेबल सारांश)
NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma or cholangiocarcinoma: 750 mg IV infusion over 4 hours every 2 weeks until disease progression or unacceptable toxicity
गर्भावस्था और स्तनपान
- गर्भावस्था
- Unsafe Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid.
- स्तनपान
- Unsafe No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
रिपोर्ट किए गए दुष्प्रभाव
- Diarrhea
- Musculoskeletal pain
- Fatigue
- Nausea
- Infusion-related reactions
- Dyspnea
बॉक्स्ड चेतावनियाँ
- Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception.
किन्हें सावधानी रखनी चाहिए
- Serious and life-threatening infusion-related reactions, hypersensitivity and anaphylaxis can occur. Give in a setting with emergency resuscitation equipment and monitor during and for at least 1 hour after the first infusion.
- Serious and life-threatening ILD/pneumonitis can occur. Monitor for new or worsening pulmonary symptoms.
- Left ventricular dysfunction can occur. Evaluate LVEF before starting and monitor at regular intervals. It has not been studied in patients with LVEF below 50% or clinically significant cardiac disease.
गर्भावस्था या स्तनपान, किडनी या लिवर के रोग, एलर्जी और आप जो भी अन्य दवा या सप्लीमेंट लेते हैं, उसके बारे में अपने फार्मासिस्ट या डॉक्टर को बताएँ।
Pro+ सदस्यों के लिए
पूरा पेज खोलें
Zenocutuzumab का पूरा मोनोग्राफ खोलने के लिए खाता बनाएँ और Pro+ ट्रायल शुरू करें: खुराक, गर्भावस्था और स्तनपान, दुष्प्रभाव, चेतावनियाँ और सभी इंटरैक्शन।
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
वेब पर Pro+ को 14 दिन मुफ़्त आज़माएँ। कार्ड की ज़रूरत नहीं।
इसी वर्ग की अन्य दवाएँ
अक्सर पूछे जाने वाले प्रश्न
What is Zenocutuzumab used for?
Zenocutuzumab is a medicine in the class oncology. It is used for Non-small cell lung cancer, Pancreatic cancer.
What side effects have been reported with Zenocutuzumab?
Diarrhea, Musculoskeletal pain, Fatigue, Nausea, Infusion-related reactions, Dyspnea. Serious warning: Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm.
Can Zenocutuzumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid. Breastfeeding: Unsafe. No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
What does Zenocutuzumab interact with?
MediHelp does not list a checked interaction for Zenocutuzumab yet. Always tell your pharmacist about every medicine you take.
MediHelp ऐप में पूर्ण मोनोग्राफ़, खुराक और इंटरैक्शन चेकर
MediHelp ऐप में पूरा संदर्भ खोलें, कई दवाओं की अंतःक्रियाएँ जाँचें और खुराक टूल इस्तेमाल करें।
